DDR2 Antibody Clears Amyloid and Boosts Memory in Mice
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- DDR2 was found in high abundance in Alzheimer’s brain tissue but is rarely present in normal human tissue, confirming its disease association.
- Jia Li and his team at Guangzhou Medical University created a monoclonal antibody that blocks DDR2, which in mouse models reduced amyloid plaques and improved spatial learning and memory.
- Shiju Gu of Harvard said targeting DDR2 could influence multiple aspects of Alzheimer’s disease, but warned that reversing the disease remains uncertain.
- César Cunha highlighted that the mouse model reflects a rare early‑onset inherited form of Alzheimer’s, raising questions about efficacy in the more common late‑onset disease.
- Clinical trial is underway using a tracer to monitor DDR2 levels in Alzheimer’s patients, and a smaller antibody is being engineered to cross the blood‑brain barrier.
Why it matters: The study provides a proof‑of‑concept that blocking DDR2 reduces amyloid‑beta accumulation and restores memory in mice, offering a novel therapeutic pathway for Alzheimer’s patients and prompting a clinical trial to test its relevance in humans, while also highlighting the need to verify efficacy in late‑onset disease.
